false 0000926617 0000926617 2025-02-05 2025-02-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 5, 2025

 

 

 

Aspira Women’s Health Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-34810   33-0595156
(State or Other Jurisdiction
of Incorporation)		  

(Commission

File Number)

   (IRS Employer
Identification No.)

 

12117 Bee Caves Road

Building III

Suite 100

    
Austin, Texas   78738
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 512 519-0400

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   AWH   The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On February 5, 2025, Dr. Sandra Milligan, the President of Aspira Women’s Health Inc. (the “Company”) informed the Board of Directors of the Company that she was resigning as President of the Company for personal reasons, effective February 21, 2025. Jamie Sullivan, Chief of Staff and ARPA-H Program Director as well as Todd Pappas, Vice President of Research &Development and Laboratory Operations, will be taking over Dr. Milligan’s duties.

 

On February 6, 2025, the Board of Directors of the Company appointed Ellen Beausang as a director of the Company.

 

Ms. Beausang has been President-Chief Commercial Officer of BioReference Health since June 2022. As an industry veteran with over 25 years of experience, Ms. Beausang has held executive roles at leading pharmaceutical and diagnostic companies including Pfizer, Thermo Fisher Diagnostics and Quest Diagnostics where she managed the go-to-market strategy and product development. Ms. Beausang holds a dual B.S. degree in Psychology/Sociology from SUNY Brockport and a M.S. Degree in Clinical Psychology from Seton Hall University.

 

There is no arrangement or understanding between Ms. Beausang and any other person pursuant to which Ms. Beausang was appointed as a director. There are no family relationships between Ms. Beausang and any of the Company’s directors, executive officers or persons nominated or chosen by the Company to become a director or executive officer. Ms. Beausang has not engaged in any related-person transactions required to be disclosed by Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended.

 

-2-
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Aspira Women’s Health Inc.
     
Date: February 10, 2025 By: /s/ Mike Buhle
    Mike Buhle, CEO

 

-3-

 

v3.25.0.1
Cover
Feb. 05, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 05, 2025
Entity File Number 001-34810
Entity Registrant Name Aspira Women’s Health Inc.
Entity Central Index Key 0000926617
Entity Tax Identification Number 33-0595156
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 12117 Bee Caves Road
Entity Address, Address Line Two Building III
Entity Address, Address Line Three Suite 100
Entity Address, City or Town Austin
Entity Address, State or Province TX
Entity Address, Postal Zip Code 78738
City Area Code 512
Local Phone Number 519-0400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol AWH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Aspira Womans Health (NASDAQ:AWH)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse Aspira Womans Health
Aspira Womans Health (NASDAQ:AWH)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse Aspira Womans Health